PuSH - Publication Server of Helmholtz Zentrum München

Kleinle, S.* ; Scholz, V.* ; Benet-Pages, A. ; Wohlfrom, T.* ; Gehling, S.* ; Scharf, F.* ; Rost, S.* ; Prott, E.C.* ; Grinzinger, S.* ; Hotter, A.* ; Haug, V.* ; Niemeier, S.* ; Wiethoff-Ubrig, L.* ; Hagenacker, T.* ; Goldhahn, K.* ; von Moers, A.* ; Walter, M.* ; Reilich, P.* ; Eggermann, K.* ; Kraft, F.* ; Kurth, I.* ; Erdmann, H.* ; Holinski-Feder, E.* ; Neuhann, T.* ; Abicht, A.*

Closing the Gap - Detection of 5q-spinal muscular atrophy by short-read Next-generation sequencing and unexpected results in a diagnostic patient cohort.

J. Neuromuscul. Dis. 10, 835-846 (2023)
Publ. Version/Full Text DOI PMC
Open Access Gold (Paid Option)
BACKGROUND: The importance of early diagnosis of 5q-Spinal muscular atrophy (5q-SMA) has heightened as early intervention can significantly improve clinical outcomes. In 96% of cases, 5q-SMA is caused by a homozygous deletion of SMN1. Around 4 % of patients carry a SMN1 deletion and a single-nucleotide variant (SNV) on the other allele. Traditionally, diagnosis is based on multiplex ligation probe amplification (MLPA) to detect homozygous or heterozygous exon 7 deletions in SMN1. Due to high homologies within the SMN1/SMN2 locus, sequence analysis to identify SNVs of the SMN1 gene is unreliable by standard Sanger or short-read next-generation sequencing (srNGS) methods. OBJECTIVE: The objective was to overcome the limitations in high-throughput srNGS with the aim of providing SMA patients with a fast and reliable diagnosis to enable their timely therapy. METHODS: A bioinformatics workflow to detect homozygous SMN1 deletions and SMN1 SNVs on srNGS analysis was applied to diagnostic whole exome and panel testing for suggested neuromuscular disorders (1684 patients) and to fetal samples in prenatal diagnostics (260 patients). SNVs were detected by aligning sequencing reads from SMN1 and SMN2 to an SMN1 reference sequence. Homozygous SMN1 deletions were identified by filtering sequence reads for the ,, gene-determining variant" (GDV). RESULTS: 10 patients were diagnosed with 5q-SMA based on (i) SMN1 deletion and hemizygous SNV (2 patients), (ii) homozygous SMN1 deletion (6 patients), and (iii) compound heterozygous SNVs in SMN1 (2 patients). CONCLUSIONS: Applying our workflow in srNGS-based panel and whole exome sequencing (WES) is crucial in a clinical laboratory, as otherwise patients with an atypical clinical presentation initially not suspected to suffer from SMA remain undiagnosed.
Altmetric
Additional Metrics?
[➜Log in]
Edit extra informations Login
Publication type Article: Journal article
Document type Scientific Article
Corresponding Author
Keywords 5q-sma ; Bioninformatics ; Clinical Genetics ; Dark Genes ; Neuromuscular Disorders ; Spinal Muscular Atrophy; Management; Genomics
ISSN (print) / ISBN 2214-3599
e-ISSN 2214-3602
Journal Journal of neuromuscular diseases
Quellenangaben Volume: 10, Issue: 5, Pages: 835-846 Article Number: , Supplement: ,
Publisher IOS Press
Publishing Place Amsterdam
Non-patent literature Publications
Reviewing status Peer reviewed
Institute(s) Institute of Neurogenomics (ING)
Grants Medical Genetic Center